公开(公告)号：US20160257741A1

公开(公告)日：2016-09-08

申请号：US15014945

申请日：2016-02-03

申请人： Medimmune Limited

发明人： Tristan John Vaughan ,  Alison Jane Wilton ,  Stephen Smith ,  Sarah Helen Main

IPC分类号： C07K16/24

摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.

摘要翻译： 针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。 本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体VH和/或VL结构域.CAT-213 / -213VH和/或VL结构域的一个或多个互补决定区（CDR） 特别是VH CRD3在其他抗体框架区域。 含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的应用，包括治疗方法或人或动物体内的治疗方法。

公开(公告)号：US09284589B2

公开(公告)日：2016-03-15

申请号：US14223561

申请日：2014-03-24

申请人： Medimmune Limited

发明人： Tristan John Vaughan ,  Alison Jane Wilton ,  Stephen Smith ,  Sarah Helen Main

IPC分类号： C12P21/04 ,  C12P21/00 ,  C07K16/24 ,  C07K16/00 ,  A61K39/00

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12P21/00

摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.

摘要翻译： 针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。 本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体V H和/或VL结构域.CAT-212 / -213VV和/或VL结构域的一个或多个互补决定区（CDR） ，特别是VH CRD3在其他抗体框架区域。 含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

公开(公告)号：US20140294857A1

公开(公告)日：2014-10-02

申请号：US14223561

申请日：2014-03-24

申请人： Medimmune Limited

发明人： Tristan John Vaughan ,  Alison Jane Wilton ,  Stephen Smith ,  Sarah Helen Main

IPC分类号： C12P21/00

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12P21/00

摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy.

摘要翻译： 针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。 本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体V H和/或VL结构域.CAT-212 / -213VV和/或VL结构域的一个或多个互补决定区（CDR） ，特别是VH CRD3在其他抗体框架区域。 含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

公开(公告)号：US20210277103A1

公开(公告)日：2021-09-09

申请号：US17011379

申请日：2020-09-03

申请人： Medimmune Limited

发明人： Tristan John VAUGHAN ,  Alison Jane Wilton ,  Stephen J. Smith ,  Sarah Helen Main

IPC分类号： C07K16/24 ,  C12P21/00

摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy.

公开(公告)号：US10577413B2

公开(公告)日：2020-03-03

申请号：US15014945

申请日：2016-02-03

申请人： Medimmune Limited

发明人： Tristan John Vaughan ,  Alison Jane Wilton ,  Stephen Smith ,  Sarah Helen Main

IPC分类号： A61K39/395 ,  A61K39/40 ,  C07K16/24 ,  C12P21/00 ,  C07K1/00 ,  A61K39/00

摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.